Clinical trial
Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
NCT00305084 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00305084 |
|---|---|
| Title | Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors |
| Official title | A Phase IB Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Solid Tumors |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | NGR-hTNF, Doxorubicin |
| Enrollment | 15 |
| Start date | Feb 28, 2006 |
| Primary completion | May 8, 2007 |
| Completion | May 8, 2007 |
| First posted | Mar 21, 2006 |
| Last update posted | Oct 4, 2019 |
| Countries | Italy, Netherlands |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: